Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

Saved in:
Bibliographic Details
Title: Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.
Authors: Breukers SE; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Traets JJH; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Dijk SW; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Ostos MM; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Fraterman I; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Crommelin RD; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Hulst H; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Qiao X; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Boere T; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Poll-Franse LV; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Retèl V; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Vos JL; Head and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Toppenberg AGL; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Heijden M; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Missale F; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Balm F; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Brekel M; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Dirven R; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Karakullukcu MB; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Karssemakers L; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Klop WMC; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Lohuis PJFM; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schreuder WH; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Maxillofacial Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands., Smeele LE; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Maxillofacial Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands., van der Velden LA; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Plasmeijer E; Department of Dermatology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Smit LA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Boer JP; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Navran A; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Westerink B; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Koekkoek-Doll PK; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Castelijns J; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Wondergem M; Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., Vogel WV; Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kuijpers A; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Houdt WJ; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Onderwater S; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Maas-Bannink E; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Cornelissen S; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Tijink BM; Department of Head and Neck Surgery & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Devriese LA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., de Bree R; Department of Head and Neck Surgery & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Hematology and Oncology, University Clinic Regensburg (UKR), Regensburg, Germany., Schumacher TN; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Thommen DS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Haanen JBAG; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Zuur CL; Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.zuur@nki.nl.; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.zuur@nki.nl.; Department of Otorhinolaryngology, Head and Neck Surgery, Leiden University Medical Center, Leiden, The Netherlands. c.zuur@nki.nl.
Source: Nature medicine [Nat Med] 2025 Dec; Vol. 31 (12), pp. 4055-4064. Date of Electronic Publication: 2025 Oct 08.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-025-03943-w